book icon

HIV Prevention Knowledge Base

A Collection of Research and Tools to Help You Find What Works in Prevention

Biomedical Interventions: Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention

Link to important additional materials and websites

PrEP Using Daily Oral TDF/FTC or TDF in Women (and Men): What the Science Tells Us in March 2012

AIDS Vaccine Advocacy Coalition. (2012).

This one-page brief, aimed at advocates, summarizes the implications of concluded and ongoing clinical trials and other research on pre-exposure prophylaxis (PrEP), including new information presented at the 2012 Conference on Retroviruses and Opportunistic Infections. It states that PrEP using a daily oral tenofovir (TDF) or TDF/emtricitabine (FTC) tablet reduces the risk of HIV in women and men, and summarizes the information to support this statement. It provides brief descriptions of information to support additional conclusions from PrEP research to date, underscoring that adherence is critical to effectiveness, that risk perception appears to contribute to an individual’s willingness and ability to adhere to the daily regimen, and that regular HIV testing is and will remain critical to addressing resistance. Finally, the brief identifies pregnant women and adolescents as among the key groups where more data are needed.

pdf View Report outside link (PDF, 222 KB)


Partners PrEP Study Demonstrates that PrEP Significantly Reduces HIV Risk: Key Messages

University of Washington, International Clinical Research Center. (2011).

This document lists “key messages” prepared by the study team in anticipation of the release of results from the Partners PrEP study. Randomization was stopped early at the recommendation of the trial’s independent Data Safety and Monitoring Board due to overwhelming evidence of effectiveness, and results were announced at the International AIDS Conference in July 2011, just a week later. This document provides an overview of the trial, its conduct, the trial findings, and their implications for pre-exposure prophylaxis in these and other populations.

pdf View Report outside link (PDF, 64 KB)


PrEP Implementation Policy Forum: Developing Country-level Preparation and Capacity for PrEP Implementation

International AIDS Society. (2007).

This report contains proceedings of a policy forum focused on country-level preparedness for pre-exposure prophylaxis (PrEP). It outlines approaches for translating research into policy and deriving lessons from implementation planning for male circumcision for HIV prevention. Ministry of Health representatives from several key countries emphasized that country-level preparedness will be predicated on the evidence, defining target populations, cost and financing, and addressing stigma and integration into existing health systems. The report also addresses designing global and national PrEP guidelines and affordability and availability of PrEP drugs. It concludes with 10 “Key Take Home Messages” to consider in preparing for PrEP implementation.

pdf View Report outside link (PDF, 162 KB)


Criteria for Drugs Used in Pre-exposure Prophylaxis Trials against HIV Infection

Derdelinckx, I., Wainberg, M. A., Lange, J. M., et al. PLoS Medicine (2006), Vol. 3, p. e454.

This paper proposes criteria for deciding which medications should be used for pre-exposure prophylaxis (PrEP). Drug safety is a critical consideration because PrEP is given to healthy individuals for long-term prevention. Drugs used for PrEP must be potent against HIV, easy to use, cost-effective, and have a high barrier to resistance. Theoretically, drugs that interfere with HIV replication before the virus enters the host cell are preferable. An ideal PrEP drug would also have a unique resistance profile and not be used in treatment of established HIV infection, but such a medication does not yet exist.

View Full Study outside link